Although in our study only TMB was statistically significant and the other factors were not, due to the small number of samples of rare variants, PD-L1/PD-1 inhibitor treatment should be considered for the treatment rare variant NSCLC tumors in the future, as they are expected to respond better than wild-type ones. This evidence concerns the gene CD274 and non-small cell lung carcinoma.